COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2

COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2

Stephen C. Harmer, Jules C. Hancox, Andrew F. James, Richard Bond, Aziza El Harchi, Alexander Carpenter, Owen J. Chambers, Oliver Hanington

The COVID-19 pandemic is an unprecedented challenge and will require novel therapeutic strategies. Affected patients are likely to be at risk of arrhythmia due to underlying comorbidities, polypharmacy and the disease process. Importantly, a number of the medications likely to receive significant use can themselves, particularly in combination, be pro-arrhythmic. Drug-induced prolongation of the QT interval is primarily caused by inhibition of the hERG potassium channel either directly and/or by impaired channel trafficking. Concurrent use of multiple hERG-blocking drugs may have a synergistic rather than additive effect which, in addition to any pre-existing polypharmacy, critical illness or electrolyte imbalance, may significantly increase the risk of arrhythmia and Torsades de Pointes. Knowledge of these risks will allow informed decisions regarding appropriate therapeutics and monitoring to keep our patients safe.

2020

arrhythmia, Drug safety, hERG, QT, QTc, COVID-19

DOI: 10.3389/fcvm.2020.00085

Frontiers in Cardiovascular Medicine

Frontiers Media S.A.

Diseases of the circulatory (Cardiovascular) system